Advances in pediatric neuro-oncology

Current Opinion in Neurology

Volumn 13, Issue 6, 2000, Pages 627-634

  Kieran, Mark W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; HUMAN; NEUROPATHOLOGY; NEURORADIOLOGY; REVIEW;

CHILD; HUMANS; NERVOUS SYSTEM NEOPLASMS;

EID: 0034532732     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200012000-00003     Document Type: Review

References (100)

1. Neonatal brain tumors: A review
2. Neuro-oncology: An overview
3. Pediatric brain tumors
4. Brain tumors in children
5. Pediatric brain tumors
6. Innovative therapies for pediatric brain tumors
7. Electrocorticographic coherence patterns
8. Neuronavigation in intraoperative MRI
9. Experiences with cranial neuronavigation in pediatric neurosurgery
10. Computer aided surgery with special focus on neuronavigation
11. Comparison of fMRI and intraoperative direct cortical stimulation in localization of receptive language areas
12. Intraoperative direct subcortical stimulation for identification of the internal capsule, combined with an image-guided stereotactic system during surgery for basal ganglia lesions
13. Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit
14. Use of a portable CT scanner during resection of subcortical supratentorial astrocytomas of childhood
15. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors
16. The role of surgery in pediatric gliomas
17. The impact of extent of resection in the management of malignant gliomas of childhood
18. Novel radiation technologies for malignant gliomas
19. Stereotactic radiation in primary brain tumors in children and adolescents
20. Impact of targeting deviations on outcome in medulloblastoma: Study of the French Society of Pediatric Oncology (SFOP)
21. Clinical and financial issues for intensity-modulated radiation therapy delivery
22. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
23. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas
24. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: Results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group
25. Concurrent chemotherapy and radiotherapy in patients with brain tumors
26. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: Results of a phase II study
27. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy
28. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study
29. Proton beam therapy (PT) in the management of CNS tumors in childhood
30. The radiation biology of boron neutron capture therapy
31. Boron neutron capture therapy of brain tumors: Enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine
32. An analysis of the late effects of radiotherapy in pediatric central nervous system tumors
33. Brachytherapy for brain tumor
34. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
35. The role of radiosurgery for glial neoplasms
36. Stereotactic radiosurgery for recurrent ependymoma
37. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy
38. Chemotherapy for childhood brain tumors: An appraisal for the millennium
39. Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review
40. Radiotherapy followed by high dose busulfan and thiotepa: A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas
41. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group phase II Study
42. Chemotherapy for low-grade gliomas
43. Perspectives: Chemotherapy of medulloblastoma
44. Germ cell tumors of the CNS in children: Recent advances in therapy
45. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors: A reappraisal
46. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans
47. Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy
48. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors
49. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)benzylguanine in vitro and in vivo
50. Topotecan for the treatment of recurrent or progressive central nervous system tumors: A pediatric oncology group phase II study
51. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration
52. A review of gene therapy for the treatment of central nervous system tumors
53. Gene transfer technologies for malignant gliomas
54. Gene therapy of malignant gliomas: A phase I study of IL- 4-HSV-TK gene-modified autologous tumor to elicit an immune response
55. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study
56. Multicolumn infusion of gene therapy cells into human brain tumors: Technical report
57. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities
58. Mechanisms of angiogenesis in the brain
59. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors
60. Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific immunotherapy and diagnostic markers
61. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma
62. Prognostic significance of DNA ploidy in childhood astrocytomas
63. Genetic alterations in pediatric high-grade astrocytomas
64. Pathology of pediatric brain tumors
65. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
66. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor
67. Cytogenetic and molecular genetic abnormalities in primitive neuroectodermal tumors of the central nervous system
68. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
69. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood
70. Coexpression of genes involved in apoptosis in central nervous system neoplasms
71. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor
72. Congenital disseminated malignant rhabdoid tumor: A distinct clinicopathologic entity demonstrating abnormalities of chromosome 22q11
73. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene
74. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
75. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
76. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas
77. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: Evidence for a medulloblastoma subtype derived from the external granule cell layer
78. Expression of bisecting GIcNAc in pediatric brain tumors and its association with tumor cell response to vinblastine
79. Imaging of brain tumors in the pediatric population
80. Tumor volume and growth kinetics in hypothalamic-chiasmatic pediatric low grade gliomas
81. Brain mapping in sedated infants and young children with passive-functional magnetic resonance imaging
82. Proton magnetic resonance spectroscopy of primary pediatric brain tumors: Neuropathological correlation
83. Three-dimensional multivoxel proton MR spectroscopy of the brain in children with neurofibromatosis type 1
84. Imaging the central nervous system effects of radiation and chemotherapy of pediatric tumors
85. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors
86. Clinical impact of MR spectroscopy when MR imaging is indeterminate for pediatric brain tumors
87. Variation of post-treatment H-MRSI choline intensity in pediatric gliomas
88. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors
89. Decreased BOLD functional MR activation of the motor and sensory cortices adjacent to a glioblastoma multiforme: Implications for image-guided neurosurgery
90. Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas
91. Parental occupation and other factors and cancer risk in children: I. Study methodology and non-occupational factors
92. Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the United States
93. Epidemiologic impact of children with brain tumors
94. The role of nutritional habits during gestation and child life in pediatric brain tumor etiology
95. Identification in human brain tumors of DNA sequences specific for SV40 large T antigen
96. Health status in 52 long-term survivors of pediatric brain tumors
97. Growth failure after treatment of pediatric brain tumors
98. Comparison of screening instruments for disability and emotional/behavioral disorders with a generic measure of health-related quality of life in survivors of childhood brain tumors
99. Neurocognitive deficits in medulloblastoma survivors and white matter loss